-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabatolimab in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Gliosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabatolimab in Gliosarcoma Drug Details: Sabatolimab is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zerlasiran in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zerlasiran in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zerlasiran in Atherosclerosis Drug Details: SLN-360 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belimumab in Cryoglobulinemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belimumab in Cryoglobulinemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belimumab in Cryoglobulinemia Drug Details: Belimumab (Benlysta) is a human IgG1 monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tasimelteon in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tasimelteon in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tasimelteon in Insomnia Drug Details: Tasimelteon (Hetlioz) is a derivative of benzofuran acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lunsekimig in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lunsekimig in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lunsekimig in Asthma Drug Details: SAR-443765 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anifrolumab in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anifrolumab in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anifrolumab in Vitiligo Drug Details: Anifrolumab (Saphnelo) is a immunoglobulin G1 kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Melanoma Drug Details: Ampligen is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elotuzumab in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elotuzumab in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elotuzumab in Myelofibrosis Drug Details: Elotuzumab (HuLuc63/Empliciti) is a humanized anti-CS1 monoclonal IgG1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Siltuximab in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Siltuximab in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Siltuximab in Pain Drug Details: Siltuximab (Sylvant), is an anti-IL-6 chimeric monoclonal antibody....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab in Osteosarcoma Drug Details: Dinutuximab (Unituxin) is a chimeric monoclonal antibody, composed...